Corvus Pharma Com (CRVS) Stock Price, Quote & News

Latest News on CRVS

Mar 28, 2025, 9:30 AM EDT - 6 days ago

Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials

Mar 28, 2025, 9:29 AM EDT - 6 days ago

Corvus Pharmaceuticals: Now At Cruising Altitude

Mar 25, 2025, 7:58 PM EDT - 9 days ago

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 4:01 PM EDT - 9 days ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 20, 2025, 8:00 AM EDT - 14 days ago

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Mar 19, 2025, 4:01 PM EDT - 15 days ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 17, 2025, 4:01 PM EDT - 17 days ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Mar 12, 2025, 8:00 AM EDT - 22 days ago

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Feb 4, 2025, 8:00 AM EST - 2 months ago

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 13, 2025, 7:30 AM EST - 2 months ago

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jan 7, 2025, 4:01 PM EST - 3 months ago

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 1:36 PM EST - 3 months ago

Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting

Dec 18, 2024, 1:23 PM EST - 3 months ago

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

Dec 18, 2024, 8:42 AM EST - 3 months ago

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

HEI TSLA

Dec 18, 2024, 7:30 AM EST - 3 months ago

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Dec 17, 2024, 4:01 PM EST - 3 months ago

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Dec 4, 2024, 4:05 PM EST - 4 months ago

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Nov 14, 2024, 10:01 AM EST - 5 months ago

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Nov 13, 2024, 1:18 PM EST - 5 months ago

Corvus Pharmaceuticals: The Market Likes The Story

Nov 13, 2024, 12:02 AM EST - 5 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:01 PM EST - 5 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 9, 2024, 1:40 PM EST - 5 months ago

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Nov 5, 2024, 4:02 PM EST - 5 months ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Sep 17, 2024, 8:00 AM EDT - 7 months ago

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

$Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma$

Sep 10, 2024, 8:30 AM EDT - 7 months ago

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Sep 3, 2024, 4:05 PM EDT - 7 months ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 7:03 AM EDT - 7 months ago

Corvus Pharmaceuticals Eyes Phase 3 Trials: Soquelitinib's Promise In PTCL

Aug 9, 2024, 10:22 PM EDT - 8 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:01 PM EDT - 8 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

$Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)$